Ripretinib (QINLOCK®) is a next-generation targeted therapy that marks a significant advancement in the treatment of gastrointestinal stromal tumors (GIST). Designed to address the challenges of tumor heterogeneity and drug resistance, ripretinib offers a vital treatment option for patients with advanced disease who have progressed after multiple lines of therapy.

With its innovative switch-control inhibition mechanism, ripretinib delivers broad and durable suppression of oncogenic KIT and PDGFRA signaling, setting a new standard in precision treatment for GIST.

Leveraging years of deep expertise in the pharmaceutical industry, DengyueMed provides a comprehensive analysis of this important targeted therapy, covering its mechanism of action, target patient population, clinical evidence, and future development prospects.

A Novel Mechanism Designed to Overcome Resistance

GIST is predominantly driven by activating mutations in the KIT and PDGFRA genes. While first-generation tyrosine kinase inhibitors (TKIs) can effectively target initial mutations, disease progression often occurs due to the emergence of secondary resistance mutations.

Ripretinib was purposefully engineered to overcome this limitation. As a broad-spectrum KIT and PDGFRA kinase inhibitor, it stabilizes these kinases in their inactive conformation, enabling comprehensive inhibition across a wide range of clinically relevant mutations.

Ripretinib inhibits mutations in KIT exons 9, 11, 13, 14, 17, and 18, as well as PDGFRA exons 12, 14, and 18, including the challenging PDGFRA D842V mutation. This extensive mutation coverage allows ripretinib to address both primary and acquired resistance, delivering consistent tumor control where other therapies may fail.

Filling a Critical Gap in Advanced GIST Treatment

Despite the availability of multiple TKIs, many patients with GIST eventually experience disease progression after standard therapies such as imatinib, sunitinib, and regorafenib. Until recently, treatment options for these heavily pretreated patients were extremely limited.

Based on results from the pivotal phase III INVICTUS trial, ripretinib became the first therapy approved globally for fourth-line treatment of advanced GIST, offering renewed hope to patients with few remaining options. Today, ripretinib is approved in multiple countries and regions worldwide, including the United States, the European Union, and China.

Ongoing clinical research continues to explore ripretinib’s potential in earlier lines of therapy and in specific molecular subtypes, further expanding its role in the GIST treatment landscape.

Clinically Proven Survival Benefits

The efficacy of ripretinib is supported by robust clinical evidence. In the INVICTUS trial, ripretinib significantly improved outcomes in patients with advanced GIST who had received three or more prior kinase inhibitors.

• Median progression-free survival (PFS): 6.3 months vs. 1.0 month with placebo

• 85% reduction in the risk of disease progression or death

• Median overall survival (OS): 15.1 months vs. 6.6 months with placebo

Ripretinib also demonstrated meaningful tumor control, with a superior objective response rate compared with placebo, reinforcing its clinical value in heavily pretreated populations.

In the INTRIGUE trial, ripretinib showed overall survival comparable to sunitinib in the second-line setting, while offering a more favorable safety profile—supporting flexible and patient-centered treatment sequencing.

Manageable Safety, Designed for Long-Term Treatment

Ripretinib has demonstrated a predictable and manageable safety profile, with fewer high-grade treatment-related adverse events compared with traditional TKIs. This allows patients to remain on therapy longer and supports sustained disease control in advanced-stage treatment.

Expanding the Future of Precision Oncology

Beyond GIST, the unique mechanism of ripretinib offers potential across other KIT- and PDGFRA-driven malignancies, with ongoing studies evaluating its role in additional indications such as systemic mastocytosis.

As clinical research advances and access continues to expand globally, ripretinib is positioned to benefit an increasing number of patients worldwide.

A New Standard for Advanced GIST

By combining broad mutation coverage, clinically proven survival benefits, and a patient-friendly safety profile, ripretinib represents a meaningful step forward in the evolution of targeted cancer therapy.

Ripretinib — advancing precision treatment for patients who need it most.